Rightslink® by Copyright Clearance Center

BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study

Author:

Yuxiang Ma,Yan Huang,Yuanyuan Zhao,Shen Zhao,Jinhui Xue,Yunpeng Yang,Wenfeng Fang,Ye Guo,Yaqian Han,Kunyu Yang,Yongsheng Li,Jun Yang,Zhenming Fu,Gang Chen,Likun Chen,Ningning Zhou,Ting Zhou,Yaxiong Zhang,Huaqiang Zhou,Qianwen Liu,Yi Zhu,Hai Zhu et al.

Publication:

The Lancet Oncology

Publisher:

Elsevier

Date:

July 2024

Please select your organization and/or account

Organization

Account

Please select your account from the above dropdown list. These accounts represent the offices, campuses, and other sites where your organization operates. Your account selection should match where you typically have an office or workspace. Even when you are traveling or temporarily working elsewhere, you should select the account that represents where you customarily work.

Cancel OK

Creative Commons

This is an open access article distributed under the terms of the Creative Commons CC-BY license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

You are not required to obtain permission to reuse this article.